Idera Announces Appointment of Jonathan Yingling, Ph.D. as Senior Vice President of Early Development
February 06 2017 - 8:00AM
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage
biopharmaceutical company developing toll-like receptor and RNA
therapeutics for patients with cancer and rare diseases, today
announced the appointment of Jonathan Yingling, Ph.D. as Senior
Vice President of Early Development. Dr. Yingling was most
recently the Chief Scientific Officer of Bind Therapeutics, Inc.,
and had previously served as Vice President of Oncology Discovery
and Translational Research at Bristol Myers Squibb and
Company. In this newly created position, Dr. Yingling will
lead and execute the early development strategy and programs
necessary to validate further immune-oncology indications for
IMO-2125 as well driving the overall third-generation antisense
(3GA) platform technology strategy.
“As we have continued to evolve as an organization focused on
delivering solutions to patients suffering from rare diseases and
cancers, it’s increasingly clear that Idera and its future can
significantly benefit from Jonathan’s expertise and track record of
strategic direction and development of candidates from early
research stage into clinical development,” stated Vincent Milano,
Idera’s Chief Executive Officer. “A world of opportunity
stands in front of us for both IMO-2125 and the 3GA platform and
Jonathan has proven throughout his career a gift for identifying
and driving those opportunities forward into successful commercial
value drivers.”
In addition to his tenures at Bind Therapeutics and Bristol
Myers Squibb & Company, Dr. Yingling had spent over a decade
leading significant oncology development activities as well as drug
candidate identification and M&A activities at Eli Lilly and
Company. Dr. Yingling received his Ph.D. from Duke University
and his Bachelor of Science from the College of William and
Mary.
“I am thrilled to be joining Idera at this pivotal time when
drug candidates are beginning to demonstrate their promise in a
clinical environment,” stated Dr. Yingling. “Both IMO-2125
and the 3GA platform have tremendous expansion potential and I am
thrilled to be here today to lead the strategic direction of those
expansions.”
Inducement Grant Under NASDAQ Listing Rule
5635(c)(4)In connection with the hiring of Dr. Yingling,
the Board of Directors of the Company approved the grant to Dr.
Yingling of a stock option to purchase 275,000 shares of the
Company’s common stock. The option was granted as an
inducement equity award outside the Company’s 2013 Stock Incentive
Plan and was made as an inducement material to Dr. Yingling’s
acceptance of employment with the company. The option will
have an exercise price equal to the closing price of the Company’s
common stock on February 6, 2017. The option has a ten year
term and vests over four years, with 25% of the original number of
shares vesting on February 6, 2018 and an additional 6.25% of the
original number of shares vesting at the end of each successive
quarter thereafter, subject to Dr. Yingling’s continued service
with the Company through the applicable vesting dates.
About Idera Pharmaceuticals Idera
Pharmaceuticals is a clinical-stage biopharmaceutical company
developing novel nucleic acid-based therapies for the treatment of
certain cancers and rare diseases. Idera’s proprietary technology
involves designing synthetic oligonucleotide-based drug candidates
to modulate the activity of specific TLRs. In addition to its TLR
programs, Idera has used its proprietary knowledge to create a
third generation antisense technology platform which inhibits the
production of disease-associated proteins by targeting RNA. To
learn more about Idera, visit www.iderapharma.com.
Investor and Media Contact
Robert Doody
VP, IR & Corporate Communications
617-679-5515 (office)
484‐639‐7235 (mobile)
rdoody@iderapharma.com
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Apr 2023 to Apr 2024